{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:32:29Z","timestamp":1790562749104,"version":"4.1.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04196-w","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T08:29:40Z","timestamp":1743841780000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combined use of Omalizumab and dupilumab: safety and efficacy data from a large academic center"],"prefix":"10.1007","volume":"317","author":[{"given":"Isabel C.","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saakshi","family":"Khattri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"4196_CR1","doi-asserted-by":"publisher","unstructured":"Chiarella SE (2019) Immunobiologic treatments for severe asthma, atopic dermatitis, and chronic urticaria. Allergy Asthma Proc 40(6):485\u2013489. https:\/\/doi.org\/10.2500\/aap.2019.40.4277. PMID: 31690400","DOI":"10.2500\/aap.2019.40.4277"},{"issue":"2","key":"4196_CR2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaad.2020.02.055","volume":"84","author":"N Ravnborg","year":"2021","unstructured":"Ravnborg N, Ambikaibalan D, Agnihotri G, Price S, Rastogi S, Patel KR, Singam V, Andersen Y, Halling AS, Silverberg JI, Egeberg A, Thyssen JP (2021) Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis. J Am Acad Dermatol 84(2):471\u2013478 Epub 2020 Feb 26. PMID: 32112994","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4196_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ajd.13743","volume":"63","author":"A Arasu","year":"2022","unstructured":"Arasu A, Sharma N, Yazdabadi A, Sladden M (2022) Dual biologic therapy with Omalizumab and dupilumab for refractory atopic disease. Australas J Dermatol 63(1):110\u2013111. https:\/\/doi.org\/10.1111\/ajd.13743Epub 2021 Nov 10. PMID: 34755893","journal-title":"Australas J Dermatol"},{"issue":"2","key":"4196_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaad.2016.08.047","volume":"76","author":"YM Andersen","year":"2017","unstructured":"Andersen YM, Egeberg A, Gislason GH, Skov L, Thyssen JP (2017) Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol 76(2):274\u2013280e1. https:\/\/doi.org\/10.1016\/j.jaad.2016.08.047","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"4196_CR5","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1111\/ijd.16009","volume":"61","author":"JG Holm","year":"2022","unstructured":"Holm JG, S\u00f8rensen JA, Thomsen SF (2022) Concurrent use of Omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis. Int J Dermatol 61(5):e173\u2013e174. https:\/\/doi.org\/10.1111\/ijd.16009Epub 2021 Nov 23. PMID: 34813086","journal-title":"Int J Dermatol"},{"key":"4196_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5414\/ALX02382E","volume":"7","author":"V Puxkandl","year":"2023","unstructured":"Puxkandl V, Hoetzenecker W, Altrichter S (2023) Case report: severe chronic spontaneous urticaria successfully treated with Omalizumab and dupilumab. Allergol Select 7:17\u201319. https:\/\/doi.org\/10.5414\/ALX02382EPMID: 36644012; PMCID: PMC9835203","journal-title":"Allergol Select"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04196-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T08:29:41Z","timestamp":1743841781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04196-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":6,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4196"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04196-w","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board of the Mount Sinai School of Medicine, in accordance with Mount Sinai\u2019s Federal Wide Assurances (FWA#00005656, FWA#00005651) to the Department of Health and Human Services approved the following human subject research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval"}},{"value":"Author SK is an employee of Mount Sinai and receives research funds from Leo Pharma, Abbvie, Bristol Myers Squibb, Pfizer, Celgene, and Acelyrin. SK is also a consultant for Leo, Abbvie, Eli Lilly, Janssen, Regeneron, Sanofi, and UCB. Author IS and RD have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"674"}}